Patent · US Active

ROR1 antibody immunoconjugates

US10335496B2 · kind B2 · utility

7Cited by
24References
84Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 5, 2018
Grant dateJul 2, 2019
Priority date—
Expiry dateJul 5, 2038

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-fragment fragment thereof and a drug moiety. These immunoconjugates are useful for treating ROR1 expressing cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.